FIELD: biotechnology.
SUBSTANCE: this invention relates to humanized antibodies that specifically recognize and bind to phosphorylated pathological Tau protein conformers, as well as to methods and compositions including these antibodies for therapeutic and diagnostic applications in the treatment of taupathies, including Alzheimer's disease (AD).
EFFECT: invention allows to effectively diagnose and improve the quality of treatment of diseases associated with tau protein.
49 cl, 6 dwg, 10 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHOSPHO-SPECIFIC ANTIBODIES RECOGNIZING TAU | 2012 |
|
RU2639537C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2603078C2 |
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
| HUMANISED TAU ANTIBODIES IN ALZHEIMER DISEASE | 2015 |
|
RU2730668C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
| HUMANISED ANTI-TAU ANTIBODIES | 2015 |
|
RU2743152C2 |
